High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients
Sammy Huygens(Ghent University Hospital), Bart Rijnders(Rega Institute for Medical Research), Arvind Gharbharan(Erasmus MC), Susanne Bogers(Erasmus MC), Bas Franken(Medisch Centrum Leeuwarden), Yasmina Serroukh(Erasmus MC), Corine H. GeurtsvanKessel(Pulmonary Associates), Bas B. Oude Munnink(University of Amsterdam), Britt Snoek(Erasmus MC), P. Martin van Hagen(Erasmus MC)
Cited by 23
Related Papers
Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2009|3.6k
SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients
|Science Immunology|2021|591
Clearance of influenza virus from the lung depends on migratory langerin+CD11b− but not plasmacytoid dendritic cells
|The Journal of Experimental Medicine|2008|465